Innovative Cancer Drugs: Medicolegal Assessments on Efficacy and Necessity
Sakarya Medical Journal · 28.03.2026 · 16 (1) · 118-126
DOI: 10.31832/smj.1798059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sakarya Medical Journal, online erschienen am 28.03.2026. Verfasst von Caner Beşkoç und 6 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
In recent years, targeted therapies and immune checkpoint inhibitors have provided significant gains in survival and quality of life compared to conventional chemotherapies. However, due to biomarker-based selectivity, high cost, and reimbursement restrictions, the concepts of “necessity” and “indication appropriateness” have become controversial from a medicolegal perspective. This study aimed to evaluate the clinical and forensic aspects of innovative cancer drug use by reviewing court case files.
Methods
A total of 455 case files submitted between January 1, 2022 and May 31, 2025, were retrospectively analyzed. Demographic data, cancer type and stage, histological subtype, performance status, previous treatments, innovative drug active agents, licensing and indication status, therapeutic intent, and council and board decisions were recorded. Data were evaluated using descriptive statistics.
Results
Of the cases, 53.6% were female and 46.4% male; the most common age group was ≥65 years. The most frequent malignancies were lung (35.2%) and breast (20.0%) cancers, and 69.5% of the patients were in stage IV disease. The most frequently used drugs were pembrolizumab (29.7%), nivolumab (16.0%), and atezolizumab (12.5%). Of all uses, 99.1% were licensed and 85.1% were indication-appropriate. Treatment intent was adjuvant in 48.6%, neoadjuvant in 10.1%, and post-progression in 41.1% of the cases. Multidisciplinary council decisions were documented in 47.3% of files, and the Forensic Board concluded that treatment use was “appropriate” in 97.6% of cases.
Conclusions
The findings indicate that innovative cancer drugs in Türkiye are mostly used within licensed and guideline-concordant indications. However, the lack of biomarker data and multidisciplinary council documentation constitutes an important limitation in medicolegal evaluations. Addressing these deficiencies would make therapeutic decisions more defensible both clinically and legally.
Zitieren
APA
Beşkoç, C., Ceylan, M. B., Gümüş, M., Büyükokuroğlu, M. E., Gültürk, E., Evren, M., & Aslıyüksek, H. (2026). Innovative Cancer Drugs: Medicolegal Assessments on Efficacy and Necessity. Sakarya Medical Journal, 16(1), 118-126. https://doi.org/10.31832/smj.1798059
Vancouver
Beşkoç C, Ceylan MB, Gümüş M, Büyükokuroğlu ME, Gültürk E, Evren M, et al. Innovative Cancer Drugs: Medicolegal Assessments on Efficacy and Necessity. Sakarya Medical Journal. 2026;16(1):118-126. doi:10.31832/smj.1798059
BibTeX
@article{Beko2026,
author = {Beşkoç, Caner and Ceylan, Mustafa Bilal and Gümüş, Mahmut and Büyükokuroğlu, Mehmet Emin and Gültürk, Emine and Evren, Melisa and Aslıyüksek, Hızır},
title = {Innovative Cancer Drugs: Medicolegal Assessments on Efficacy and Necessity},
journal = {Sakarya Medical Journal},
year = {2026},
volume = {16},
number = {1},
pages = {118--126},
doi = {10.31832/smj.1798059}
}
EUVIMED